EMA Presses On With Guidance On Secondary Use Of Health Data
The European Medicines Agency will use feedback from two workshops in September to clarify what data protection issues must be addressed to allow for the secondary use of health and medical data when it comes to developing, monitoring and evaluating medicines.
You may also be interested in...
Efforts to set up an EU-wide network of real-world data sources to support medicines evaluation are gathering pace.
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year by various European Medicines Agency scientific committees.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.